etidronate has been researched along with Hip Fractures in 66 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Hip Fractures: Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 7.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 5.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| "According to the data of a fracture intervention trial, in women aged 55-80 years with vertebral fractures or osteoporosis diagnosed by bone mineral density measurement, treatment with the bisphosphonate alendronate prevented hip fractures with numbers-needed-to-treat within 5 years of treatment of 46 and 66, respectively." | 4.81 | [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures]. ( Netelenbos, JC, 2001) |
| " Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures." | 3.81 | Efficacy, effectiveness and side effects of medications used to prevent fractures. ( Reid, IR, 2015) |
| " Medicines dispensed at a pharmacy which are indicated for the prevention of osteoporotic hip fractures (alendronate, risedronate and strontium ranelate)." | 3.77 | [Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain]. ( Charle-Crespo, MÁ; Gomes-Carvalho, CS; Guerra-García, MM; Prejigueiro-Santás, A; Puga-Sarmiento, E; Rodríguez-Fernández, JB, 2011) |
| "One of the patients was treated with alendronate therapy in concern of her risk factors for osteoporosis (her previous a hysterectomy with bilateral oophorectomy) with unsubstantiated evidence of her pretreatment, bone-mineral-density measurements (BMD), for a 10-year prior episode of left prodromal thigh pain and an insufficiency fracture at 8 days post experiencing the pain." | 3.77 | Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases. ( Angthong, C; Angthong, W, 2011) |
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 3.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| "New hip fractures were significantly less frequent in the risedronate group, suggesting a preventive effect in high-risk patients." | 2.77 | Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. ( Aoyagi, K; Chiba, K; Doiguchi, Y; Furuichi, I; Hashikawa, T; Motokawa, S; Norimatsu, T; Osaki, M; Shindo, H; Tatsuki, K, 2012) |
| "Urinary deoxypyridinoline, a bone resorption marker, decreased by 46." | 2.73 | Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. ( Honda, Y; Iwamoto, J; Sato, Y, 2007) |
| "The effect of risedronate treatment on bone resorption was investigated quantitatively by measuring N-telopeptide levels in urine of patients with hip fracture." | 2.73 | [The effect of risedronate treatment on bone turnover markers in patients with hip fracture]. ( Altintaş, F; Beyzadeoğlu, T; Eren, A; Güven, M; Ozkut, AT, 2007) |
| "Etidronate therapy inhibits bone resorption and improves calcium balance, and such therapy may prevent bone loss and reduce the risk of subsequent hip fracture." | 2.71 | Beneficial effect of etidronate therapy in immobilized hip fracture patients. ( Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K; Yasuda, H, 2004) |
| "Treatment with menatetrenone, risedronate or regular sunlight exposure are safe and effective in increasing bone mass and reducing the risk of hip fracture in patients with AD." | 2.46 | [Dementia and fracture]. ( Sato, Y, 2010) |
| "Neurological diseases, including Alzheimer's disease, stroke, and Parkinson's disease have been reported to increase the risk for fractures." | 2.44 | Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials. ( Iwamoto, J; Matsumoto, H; Takeda, T, 2008) |
| "In contrast to postmenopausal osteoporosis, the overriding objective in senior citizens older than 75 years is to avoid fractures of the hip, which are associated with a high mortality rate." | 2.43 | [Osteoporosis in the elderly--diagnosis and treatment]. ( Gärtner, R, 2005) |
| "The source of most hip fractures is the community." | 2.39 | Present and future of osteoporosis therapy. ( Bass, S; Pearce, G; Seeman, E; Tsalamandris, C, 1995) |
| "We observed three cohorts of women aged 65 years and older who initiated once-a-week dosing of bisphosphonate therapy; (1) patients adherent to alendronate (n = 21,615), (2) patients adherent to risedronate (n = 12,215), or (3) patients filling only a single bisphosphonate prescription (n = 5,390) as a referent population." | 1.39 | Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2013) |
| " We did not find evidence for a reversal of fracture protection with long-term use of bisphosphonates." | 1.38 | Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. ( Abrahamsen, B; Pazianas, M; Russell, RG; Wang, Y, 2012) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 1.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| "There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in patients with leprosy." | 1.33 | Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol. ( Ando, K; Higashi, M; Ichinose, H; Kanaji, A; Nakagawa, M; Namisato, M; Sakamaki, T; Yamada, H; Yato, Y, 2005) |
| "If patients with osteoporosis are being diagnosed and effective treatments used with increasing frequency in the population, rates of hip and wrist fractures will remain stable or possibly decrease." | 1.33 | Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? ( Adachi, JD; Hawker, G; Jaakkimainen, L; Jaglal, SB; Kreder, H; Mamdani, M; Weller, I, 2005) |
| "Hip fractures are the most costly and best-documented complication of osteoporosis." | 1.32 | Health-economic comparison of three recommended drugs for the treatment of osteoporosis. ( Brecht, JG; Huppertz, E; Kruse, HP; Möhrke, W; Oestreich, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.52) | 18.2507 |
| 2000's | 48 (72.73) | 29.6817 |
| 2010's | 17 (25.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lindsay, R | 2 |
| Watts, NB | 4 |
| Lange, JL | 4 |
| Delmas, PD | 2 |
| Silverman, SL | 2 |
| Anitha, D | 1 |
| Kim, KJ | 1 |
| Lim, SK | 1 |
| Lee, T | 1 |
| Reid, IR | 1 |
| Rietbrock, S | 1 |
| Olson, M | 1 |
| van Staa, TP | 1 |
| Curtis, JR | 1 |
| Westfall, AO | 1 |
| Cheng, H | 1 |
| Saag, KG | 1 |
| Delzell, E | 1 |
| Wasserfallen, JB | 1 |
| Krieg, MA | 1 |
| Greiner, RA | 1 |
| Lamy, O | 1 |
| Abelson, A | 1 |
| Ringe, JD | 1 |
| Gold, DT | 1 |
| Thomas, T | 1 |
| Masud, T | 1 |
| McClung, M | 1 |
| Geusens, P | 2 |
| Berto, P | 1 |
| Maggi, S | 1 |
| Noale, M | 1 |
| Lopatriello, S | 1 |
| Sato, Y | 7 |
| Iwamoto, J | 7 |
| Honda, Y | 4 |
| Guerra-García, MM | 1 |
| Rodríguez-Fernández, JB | 1 |
| Puga-Sarmiento, E | 1 |
| Charle-Crespo, MÁ | 1 |
| Gomes-Carvalho, CS | 1 |
| Prejigueiro-Santás, A | 1 |
| Ferrari, S | 1 |
| Nakamura, T | 1 |
| Hagino, H | 1 |
| Fujiwara, S | 1 |
| Osaki, M | 1 |
| Tatsuki, K | 1 |
| Hashikawa, T | 1 |
| Norimatsu, T | 1 |
| Chiba, K | 1 |
| Motokawa, S | 1 |
| Furuichi, I | 1 |
| Doiguchi, Y | 1 |
| Aoyagi, K | 1 |
| Shindo, H | 1 |
| Umeno, K | 1 |
| Hayashida, N | 1 |
| Takeda, T | 2 |
| Matsumoto, H | 2 |
| Ovaska, MT | 1 |
| Mäkinen, TJ | 1 |
| Madanat, R | 1 |
| Pazianas, M | 1 |
| Abrahamsen, B | 1 |
| Wang, Y | 1 |
| Russell, RG | 1 |
| Davey, DA | 1 |
| Angthong, C | 1 |
| Angthong, W | 1 |
| Kim, TY | 1 |
| Ha, YC | 1 |
| Kang, BJ | 1 |
| Lee, YK | 1 |
| Koo, KH | 1 |
| Deal, CL | 1 |
| Miller, PD | 2 |
| Kanoko, T | 2 |
| Yasuda, H | 1 |
| Satoh, K | 2 |
| Brecht, JG | 2 |
| Kruse, HP | 2 |
| Felsenberg, D | 1 |
| Möhrke, W | 2 |
| Oestreich, A | 2 |
| Huppertz, E | 2 |
| Kanaji, A | 1 |
| Higashi, M | 1 |
| Namisato, M | 1 |
| Ando, K | 1 |
| Nakagawa, M | 1 |
| Yato, Y | 1 |
| Ichinose, H | 1 |
| Sakamaki, T | 1 |
| Yamada, H | 1 |
| Bartl, R | 1 |
| Christensen, PM | 1 |
| Sørensen, HA | 1 |
| Vestergaard, P | 1 |
| Jaglal, SB | 1 |
| Weller, I | 1 |
| Mamdani, M | 2 |
| Hawker, G | 2 |
| Kreder, H | 1 |
| Jaakkimainen, L | 1 |
| Adachi, JD | 2 |
| Melton, LJ | 1 |
| Kanis, JA | 1 |
| Johnell, O | 1 |
| Poole, KE | 1 |
| Warburton, EA | 1 |
| Reeve, J | 1 |
| Muñoz, VL | 1 |
| Roger, DR | 1 |
| Valle, MB | 1 |
| García, LL | 1 |
| Hamdy, RC | 1 |
| Chesnut, CH | 1 |
| Gass, ML | 1 |
| Holick, MF | 1 |
| Leib, ES | 1 |
| Lewiecki, ME | 1 |
| Maricic, M | 1 |
| Christoffersen, H | 1 |
| Holmegaard, SN | 1 |
| Siris, ES | 1 |
| Halbekath, JM | 1 |
| Schenk, S | 1 |
| von Maxen, A | 1 |
| Meyer, G | 1 |
| Mühlhauser, I | 1 |
| Epstein, S | 1 |
| Altintaş, F | 1 |
| Ozkut, AT | 1 |
| Beyzadeoğlu, T | 1 |
| Eren, A | 1 |
| Güven, M | 1 |
| Kopp, A | 1 |
| Grima, DT | 1 |
| Papaioannou, A | 1 |
| Thompson, MF | 1 |
| Pasquale, MK | 1 |
| Itabashi, A | 1 |
| Wells, GA | 1 |
| Cranney, A | 2 |
| Peterson, J | 2 |
| Boucher, M | 2 |
| Shea, B | 2 |
| Robinson, V | 2 |
| Coyle, D | 2 |
| Tugwell, P | 2 |
| Wells, G | 1 |
| Gärtner, R | 1 |
| Seeman, E | 1 |
| Tsalamandris, C | 1 |
| Bass, S | 1 |
| Pearce, G | 1 |
| Papapoulos, SE | 1 |
| Compston, JE | 1 |
| McClung, MR | 1 |
| Zippel, H | 1 |
| Bensen, WG | 1 |
| Roux, C | 1 |
| Adami, S | 1 |
| Fogelman, I | 1 |
| Diamond, T | 1 |
| Eastell, R | 1 |
| Meunier, PJ | 2 |
| Reginster, JY | 1 |
| Goodman, RL | 1 |
| Schott, AM | 1 |
| Dargent-Molina, P | 1 |
| Royce, PC | 1 |
| Netelenbos, JC | 1 |
| Kamel, HK | 1 |
| Duthie, EH | 1 |
| Iglesias, CP | 1 |
| Torgerson, DJ | 1 |
| Bearne, A | 1 |
| Bose, U | 1 |
| Hodsman, AB | 1 |
| Hanley, DA | 1 |
| Josse, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| STOP Vertigo: Supplementation of Vitamin D for Termination of Recurrences From Benign Paroxysmal Positional Vertigo[NCT05863949] | 860 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | |||
| Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203] | Phase 2 | 120 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for etidronate and Hip Fractures
| Article | Year |
|---|---|
[Dementia and fracture].
Topics: Accidental Falls; Bone Density; Dementia; Etidronic Acid; Hip Fractures; Humans; Hyperparathyroidism | 2010 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid | 2002 |
Editorial: greater risk, greater benefit--true or false?
Topics: Calcium Channel Blockers; Etidronic Acid; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Risk | 2003 |
Review of treatment modalities for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Die | 2005 |
Patients with hip fracture: what can be improved?
Topics: Bone Density Conservation Agents; Etidronic Acid; Hip Fractures; Humans; Public Health; Risedronic A | 2006 |
Is cortical bone hip? What determines cortical bone properties?
Topics: Alendronate; Bone and Bones; Bone Density; Bone Remodeling; Etidronic Acid; Fractures, Spontaneous; | 2007 |
[HIP study--how to prevent hip fractures?].
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Hip Fr | 2007 |
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Hip Fractures; Humans; Osteo | 2008 |
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Os | 2008 |
Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials.
Topics: Age Distribution; Aged; Aged, 80 and over; Alzheimer Disease; Bone Density Conservation Agents; Conf | 2008 |
[Osteoporosis in the elderly--diagnosis and treatment].
Topics: Accidental Falls; Age Factors; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Ca | 2005 |
Present and future of osteoporosis therapy.
Topics: Bone Density; Bone Development; Bone Resorption; Calcitonin; Calcitriol; Calcium, Dietary; Diphospho | 1995 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2000 |
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
Topics: Age Factors; Aged; Alendronate; Bone Density; Calcium Channel Blockers; Diphosphonates; Etidronic Ac | 2001 |
The underuse of therapy in the secondary prevention of hip fractures.
Topics: Accidental Falls; Alendronate; Calcium; Estrogens; Etidronic Acid; Hip Fractures; Hip Prosthesis; Hu | 2002 |
12 trials available for etidronate and Hip Fractures
| Article | Year |
|---|---|
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Hip Fractures; Hu | 2009 |
RETRACTED: Beneficial effect of etidronate therapy in chronically hospitalized, disabled patients with stroke.
Topics: Aged; Body Mass Index; Bone Density; Bone Density Conservation Agents; Calcium; Chronic Disease; Dis | 2010 |
Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Epidemiologic Methods; Etid | 2012 |
The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bone Density; Bone Density Conservation Agents; Etidroni | 2011 |
Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administratio | 2011 |
Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures?
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic A | 2012 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid | 2002 |
Beneficial effect of etidronate therapy in immobilized hip fracture patients.
Topics: Aged; Bone and Bones; Bone Resorption; Calcium; Diphosphonates; Double-Blind Method; Etidronic Acid; | 2004 |
Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Topics: Accidental Falls; Aged; Bone Density; Bone Density Conservation Agents; Calcium; Double-Blind Method | 2005 |
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bo | 2007 |
[The effect of risedronate treatment on bone turnover markers in patients with hip fracture].
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collage | 2007 |
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, | 2001 |
40 other studies available for etidronate and Hip Fractures
| Article | Year |
|---|---|
Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; E | 2013 |
Implications of local osteoporosis on the efficacy of anti-resorptive drug treatment: a 3-year follow-up finite element study in risedronate-treated women.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur Neck; Finite Ele | 2013 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; | 2015 |
The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug | 2009 |
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; F | 2009 |
Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidr | 2008 |
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Meth | 2010 |
Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Costs | 2010 |
[Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Prescriptions; Etidronic Acid; Female; Hip | 2011 |
Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Etidronic Acid; Fem | 2011 |
Simultaneous bilateral subtrochanteric fractures following risedronate therapy.
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Risedr | 2011 |
Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Topics: Administration, Oral; Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedul | 2012 |
Osteoporosis, osteopenia and fracture risk: widening the therapeutic horizons.
Topics: Adult; Age Factors; Aged; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Diseases, | 2012 |
Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; F | 2011 |
Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
Topics: Aged; Calcium Channel Blockers; Cost-Benefit Analysis; Etidronic Acid; Evidence-Based Medicine; Fema | 2003 |
[Faster and long-lasting protection with risedronate. With strengthened bones longer self-sufficient].
Topics: Age Factors; Aged; Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Female; Hip F | 2004 |
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Cohort Studies; Cost-Benefit Analysis; Etidronic | 2004 |
Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol.
Topics: Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Femur; Hip Fractures; Humans; Hydroxycholecal | 2005 |
[Update 2004. Osteoporosis--management--current status].
Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Fem | 2004 |
[Evaluation of the effects of treatment of osteoporosis].
Topics: Aged; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; | 2005 |
Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong?
Topics: Aged; Aging; Bone Density; Drug Prescriptions; Etidronic Acid; Female; Fractures, Bone; Hip Fracture | 2005 |
Potential impact of osteoporosis treatment on hip fracture trends.
Topics: Aged; Bone and Bones; Bone Density; Canada; Clinical Trials as Topic; Etidronic Acid; Female; Hip Fr | 2005 |
Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Topics: Accidental Falls; Aged; Bone Density Conservation Agents; Causality; Clinical Trials as Topic; Etidr | 2005 |
[Antiresorptive treatment after proximal femur fracture].
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Drug Therapy, Combination; Etidronic Acid; H | 2005 |
[Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; F | 2005 |
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Evaluation; Etidronic A | 2007 |
Risedronate for the prevention of hip fractures: concern about validity of trials.
Topics: Aged; Bone Density Conservation Agents; Etidronic Acid; Female; Follow-Up Studies; Hip Fractures; Hu | 2007 |
[Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Etidronic Acid; Female; Fractures, Sp | 2007 |
Hip fractures in users of first- vs. second-generation bisphosphonates.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Diphosphonat | 2007 |
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Canada; Cost-B | 2008 |
[A new bisphosphonate. A vertebral body fracture seldom remains alone].
Topics: Etidronic Acid; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Spinal | 2000 |
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagoni | 2000 |
Hip fractures: do preventive drugs work for all?
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Etidronic Acid; Female; Hip Fractures; Humans; Os | 2001 |
The effect of risedronate on the risk of hip fracture in elderly women.
Topics: Aged; Calcium Channel Blockers; Data Interpretation, Statistical; Etidronic Acid; Female; Follow-Up | 2001 |
The effect of risedronate on the risk of hip fracture in elderly women.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Femur Neck; | 2001 |
The effect of risedronate on the risk of hip fracture in elderly women.
Topics: Aged; Calcium Channel Blockers; Etidronic Acid; Female; Hip Fractures; Humans; Risedronic Acid; Risk | 2001 |
[Osteoporosis. Fracture as alarm signal].
Topics: Aged; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis, Postmenop | 2001 |
[Therapy of osteoporosis. Risk factors alone are not an indication].
Topics: Aged; Aged, 80 and over; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Oste | 2001 |
The cost utility of bisphosphonate treatment in established osteoporosis.
Topics: Aged; Calcium Channel Blockers; Cost-Benefit Analysis; Etidronic Acid; Female; Hip Fractures; Humans | 2002 |
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
Topics: Aged; Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; | 2002 |